It was found that ramucirumab, a monoclonal antibody specific for VEGFR2, combined with tyrosine kinase inhibitors regorafenib and cabozantinib, present specific benefits for advanced HCC patients with high serum concentrations of AFP (68). The gene discussed is AFP; the disease is hepatocellular carcinoma.